Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of [68Ga]Ga-FAPI PET/CT in oncological patients with doubtful or inconclusive findings at [18F]F-FDG PET/CT
2024-518765-96-00Phase 2Authorised
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Nov 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga FAPI-46, sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Primary: Accuracy of 68Ga-FAPI-46 PET/CT for detecting presence of disease. Planned start Nov 2024; status: authorised.
02
Drugs
68Ga FAPI-46
Beyond the preview
Go deeper on 2024-518765-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518765-96-00.